Latest Healthcare It News

Resmed Inc. posted robust Q2 FY2026 results, with revenue climbing 11% to $1.4 billion and a 16% rise in non-GAAP earnings per share, underpinned by strong global demand and operational efficiencies.

TrivarX Limited has expanded its diagnostic portfolio by acquiring the Stabl-Im brain cancer imaging technology and reported strong clinical trial results validating its single-lead ECG algorithm for depression screening in US veterans.

Nexsen Limited has reported significant progress in its rapid diagnostic technologies, including a key FDA pre-submission for its GBS rapid sensor and a solid cash reserve post-IPO to support commercialisation efforts.

Skin Elements Limited has marked a pivotal quarter with a $2.5 million capital raise and successful product evaluations, setting the stage for commercial rollout of its natural biotechnology range in 2026.

Lumos Diagnostics reported a strong surge in FebriDx® sales alongside positive FDA feedback, securing full Medicare reimbursement and advancing key clinical studies.

BKI Investment Company Limited reported a 10% increase in net profit after tax to $34.3 million for the half-year ended 31 December 2025, alongside a modest rise in its interim dividend. The company’s portfolio performance reflected mixed sector trends amid a volatile market.

Vitura Health has announced the departure of CEO Geoff Cockerill, appointing Chief Revenue Officer Ryan Tattle as interim leader while accelerating the search for a new CEO. Incoming CFO Andrew Cook will join ahead of schedule, signalling a renewed focus on operational and financial discipline.

BrainChip Holdings has bolstered its financial position with a A$35 million capital raise and commenced volume production of its AKD1500 neuromorphic AI chip, while deepening its strategic partnership with Parsons’ defence arm.

Zelira Therapeutics has raised nearly US$33 million to fund clinical trials for its HOPE 1 cannabinoid-based medicine targeting autism, while also benefiting from a $1.07 million R&D tax refund.

Microba Life Sciences reports robust year-on-year growth in microbiome testing volumes and revenue, advancing towards regional break-even in Australia and the UK while progressing its therapeutic pipeline.

Microba Life Sciences reports a 90% year-on-year increase in core microbiome test volumes, driving a 123% rise in core testing revenue to $2.1 million, while advancing clinical adoption and cost efficiencies.

Biotron Limited has completed the acquisition of Sedarex Limited alongside a $2.5 million capital raising, while its lead Hepatitis B drug candidate BIT-HBV001 shows promising preclinical results outperforming current treatments.